




Healthcare News Roundup: BIopharmaceuticals
HSMN NewsFeed - 21 Mar 2022
NeuroSense Therapeutics Receives FDA Clearance of IND for PrimeC for the Treatment of ALS
NeuroSense Therapeutics Receives FDA Clearance of IND for PrimeC for the Treatment of ALS
HSMN NewsFeed - 18 Mar 2022
NRx Pharmaceuticals, Inc. Appoints Ira Strassberg as Chief Financial Officer and Treasurer
NRx Pharmaceuticals, Inc. Appoints Ira Strassberg as Chief Financial Officer and Treasurer
HSMN NewsFeed - 9 Mar 2022
Orna Therapeutics Bolsters Leadership Team with Key Executive and Board Appointments
Orna Therapeutics Bolsters Leadership Team with Key Executive and Board Appointments
HSMN NewsFeed - 7 Mar 2022
Elixirgen Therapeutics Partners with Taisho Pharmaceutical on Therapeutics for Aging-Associated Diseases
Elixirgen Therapeutics Partners with Taisho Pharmaceutical on Therapeutics for Aging-Associated Diseases
HSMN NewsFeed - 4 Mar 2022
Lannett Announces Sale of Liquid Drug Manufacturing Plant and Other Assets for $10.5 Million
Lannett Announces Sale of Liquid Drug Manufacturing Plant and Other Assets for $10.5 Million
HSMN NewsFeed - 22 Feb 2022
Lilly Announces the Institute for Genetic Medicine and $700 Million investment in Boston Seaport Site
Lilly Announces the Institute for Genetic Medicine and $700 Million investment in Boston Seaport Site
HSMN NewsFeed - 10 Feb 2022
GentiBio Appoints Industry Veteran Chuck Silberstein as Chief Financial Officer
GentiBio Appoints Industry Veteran Chuck Silberstein as Chief Financial Officer
HSMN NewsFeed - 7 Feb 2022
US FDA "Study May Proceed" Letter for Clarity's Cu-64 SAR-bisPSMA Trial in Prostate Cancer
US FDA "Study May Proceed" Letter for Clarity's Cu-64 SAR-bisPSMA Trial in Prostate Cancer